Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | GBA1 | P04062 | 3/20 | 0.51 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.48 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.47 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.47 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.47 |
| ▸ | GJB2 | P29033 | 1/20 | 0.46 |
| ▸ | TNF | P01375 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25415166 | 0.98 | MAPK1 (0.60) | MAPK1GBA1SLC2A1LGALS8LGALS3 | |
| SCHEMBL25415432 | 0.98 | MAPK1 (0.60) | MAPK1GBA1SLC2A1LGALS8LGALS3 | |
| SCHEMBL25414516 | 0.98 | MAPK1 (0.60) | MAPK1GBA1SLC2A1LGALS8LGALS3 | |
| SCHEMBL546864 | 0.95 | MAPK1 (0.60) | MAPK1GBA1SLC2A1LGALS8LGALS3 | |
| SCHEMBL14747620 | 0.95 | MAPK1 (0.52) | MAPK1GBA1SLC2A1LGALS8LGALS3 | |
| SCHEMBL25417760 | 0.92 | MAPK1 (0.54) | MAPK1GBA1SLC2A1LGALS8LGALS3 | |
| SCHEMBL28276208 | 0.91 | MAPK1 (0.56) | MAPK1GBA1SLC2A1LGALS8LGALS3 | |
| SCHEMBL28274960 | 0.91 | MAPK1 (0.56) | MAPK1GBA1SLC2A1LGALS8LGALS3 | |
| SCHEMBL8370478 | 0.91 | MAPK1 (0.60) | MAPK1GBA1SLC2A1LGALS8LGALS3 | |
| SCHEMBL8370481 | 0.91 | MAPK1 (0.60) | MAPK1GBA1SLC2A1LGALS8LGALS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1747961-A | Process for producing ribofuranose derivative | INALCO SPA (IT) | 2006-03-15 | — | — | CN | disclosed |
| EP-1631573-A1 | PROCESS FOR THE PREPARATION OF RIBOFURANOSE DERIVATIVES | INALCO SpA (IT) | 2006-03-08 | — | — | EP | disclosed |
| US-6891036-B2 | Process for the preparation of ribofuranose derivatives | INALCO S.P.A. (IT) | 2005-05-10 | — | — | US | disclosed |
| WO-2004069851-A1 | PROCESS FOR THE PREPARATION OF RIBOFURANOSE DERIVATIVES | INALCO S.P.A. (IT) | 2004-08-19 | — | — | WO | disclosed |
| US-20040158059-A1 | Process for the preparation of ribofuranose derivatives | INALCO S.P.A. (IT) | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040158059-A1 | Process for the preparation of ribofuranose derivatives | RNGTT, RPIA, MRM1 | MAPK1 2206/4885GBA1 1204/4885SLC2A1 1004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.